Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimoxamine SCHEMBL894999 | 1.00 | TAAR1 (0.54) | TAAR1HTR2A | |
| Dimoxamine SCHEMBL29633087 | 1.00 | TAAR1 (0.54) | TAAR1HTR2A | |
| Dimoxamine SCHEMBL43489 | 1.00 | TAAR1 (0.54) | TAAR1HTR2A | |
| Dimoxamine SCHEMBL29543489 | 1.00 | TAAR1 (0.54) | TAAR1HTR2A | |
| Dimoxamine SCHEMBL30855253 | 0.98 | TAAR1 (0.53) | TAAR1HTR2A | |
| Dimoxamine SCHEMBL3142009 | 0.98 | TAAR1 (0.53) | TAAR1HTR2A | |
| Dimoxamine SCHEMBL121888 | 0.98 | TAAR1 (0.53) | TAAR1HTR2A | |
| Dimoxamine SCHEMBL30855252 | 0.98 | TAAR1 (0.53) | TAAR1HTR2A | |
| Dimoxamine SCHEMBL3147518 | 0.97 | TAAR1 (0.51) | TAAR1HTR2A | |
| SCHEMBL11737197 | 0.91 | TAAR1 (0.45) | TAAR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9879293-B2 | Enzymatic transamination of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20160177354-A1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | SAFC, INC. | 2016-06-23 | — | — | US | disclosed |
| EP-2462115-B1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | INFINITY PHARMACEUTICALS INC (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20140371456-A1 | Enzymatic Transamination of Cyclopamine Analogs | ROYALTY SECURITY, LLC | 2014-12-18 | — | — | US | disclosed |
| US-8703448-B2 | Enzymatic transamination of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20120083607-A1 | Enzymatic Transamination of Cyclopamine Analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083607-A1 | Enzymatic Transamination of Cyclopamine Analogs | TKT, TALDO1, BCHE | TAAR1 2537/4885HTR2A 4028/4885 |
| US-20140371456-A1 | Enzymatic Transamination of Cyclopamine Analogs | TKT, TALDO1, BCHE | TAAR1 2537/4885HTR2A 4028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.